MAPT and Alzheimer disease: Literature describes sex differences in AD biomarkers, such as that females with abnormal Aβ who are APOE-ε4 carriers show greater subsequent increase in cerebrospinal fluid (CSF) tau than their male counterparts (Buckley et al., 2019), or that females with higher Aβ burden show higher entorhinal cortical tau than their male counterparts (Buckley et al., 2019).